Evidence map›Paper›PMID 26202927›Full record

ArticleLeukemia2016

Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.

N Cervera, N Carbuccia, S Garnier, A Guille, J Adélaïde, A Murati, N Vey, M-J Mozziconacci, M Chaffanet, D Birnbaum and 1 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. [Clinical characteristics and prognosis of acute erythroleukemia in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Erythroid Cell Research: 3D Chromatin, Transcription Factors and Beyond.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Review
  11. Erythroleukemia: an Update.Current oncology reports · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
    Article
  20. De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

N CerveraLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
N CarbucciaLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
S GarnierLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
A GuilleLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
J AdélaïdeLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
A MuratiLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
N VeyAix-Marseille Université, Marseille, France.
M-J MozziconacciLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
M ChaffanetLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
D BirnbaumLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.
V Gelsi-BoyerLaboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chromosome AberrationsBiomarkers, TumorFemaleHigh-Throughput Nucleotide SequencingHumansLeukemia, Erythroblastic, AcuteMaleMiddle AgedMutationNeoplasm StagingPrognosisSurvival RateBiomarkers, Tumor

Identifiers

PMID26202927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.